Oral alpha-lipoic acid to prevent chemotherapy-induced peripheral neuropathy: a randomized, double-blind, placebo-controlled trial (2014)

Peer-Reviewed Study · Guo Y, Jones D, Palmer JL, Forman A, Dakhil SR, Velasco MR, Weiss M, Gilman P, Mills GM, Noga SJ, Eng C, Overman MJ, Fisch MJ · May 2014

Guo Y et al., 2014-05: Randomised double-blind placebo-controlled trial of oral alpha-lipoic acid 600 mg three times daily for 24 weeks in patients receiving cisplatin or oxaliplatin: no significant difference in neuropathy scores, pain or function, and only 70 of 243 patients completed.

No statistically significant differences were found between the ALA and the placebo groups for FACT/GOG-Ntx scores, BPI scores, and patients' functional outcomes.

Abstract, Results and Conclusion

Guo Y et al., 2014-05: Randomised double-blind placebo-controlled trial of oral alpha-lipoic acid 600 mg three times daily for 24 weeks in patients receiving cisplatin or oxaliplatin: no significant difference in neuropathy scores, pain or function, and only 70 of 243 patients completed. Study type: randomized trial.